Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company products are sold in countries around the world. Eli Lilly products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products.
Website: lilly.com


  • Good financial results growth rate 173.5% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (44.0%)
  • Dividend yield for the last twelve months 0.6%
  • Free cash flow yield -0.5% (LTM)
  • Share price is 240.7% higher than minimum and 4.7% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (39.5x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $77 620.6 mln (-0.202% of cap.)

Key Financials (Download financials)

Ticker: LLY
Share price, USD:  (+3.7%)1058.18
year average price 856.01  


year start price 868.88 2025-02-10

min close price 625.65 2025-08-08

max close price 1109.94 2025-11-25

current price 1058.18 2026-02-09
Common stocks: 900 605 000

Dividend Yield:  0.6%
FCF Yield LTM: -0.5%
EV / LTM EBITDA: 39.5x
EV / EBITDA annualized: 31.4x
Last revenue growth (y/y):  +53.9%
Last growth of EBITDA (y/y):  +200.0%
Historical revenue growth:  +28.1%
Historical growth of EBITDA:  +59.8%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 953 002
Net Debt ($m): 32 651
EV (Enterprise Value): 985 653
EBITDA LTM ($m): 24 974
EV / LTM EBITDA: 39.5x
Price to Book: 40.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-02-07fool.com

3 Things Investors Need to Know About the Healthcare Sector in 2026

2026-02-07reuters.com

Weight-loss drugs to compete on biggest stage with Super Bowl ads

2026-02-06marketbeat.com

Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut

2026-02-05seekingalpha.com

Eli Lilly: Positives Outweigh The Concerns

2026-02-05marketbeat.com

The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles

2026-02-04seekingalpha.com

Eli Lilly and Company (LLY) Q4 2025 Earnings Call Transcript

2026-02-04investopedia.com

Eli Lilly Stock Soars While Novo Nordisk Sinks—Why the Weight-Loss Leaders Are Headed in Opposite Directions

2026-02-04zacks.com

Lilly Stock Jumps After Q4 Earnings Beat and Strong 2026 Guidance

2026-02-04schaeffersresearch.com

Eli Lilly Stock Eyes Best Day Since October After Quarterly Beat

2026-02-04proactiveinvestors.com

Eli Lilly shares soar after Q4 beat, strong forecast on weight-loss drugs
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data